MetaCap

Alpha Tau Medical Ltd. (DRTS)

NASDAQ: DRTSHealth CareMedical/Dental InstrumentsUSD

11.76+0.445 (+3.93%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DRTS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.04
52-week range
3.65 – 15.79
Day range
11.32 – 12.19
Volume / Avg
626.87K / 591.88K
Beta
—

52-week range

$3.65$15.79

DRTS stock today

On Nov 20, DRTS ended the session at $11.76, adding $0.445 (3.93%), versus the S&P 500's 3.70% decline. Shares are 25.6% below their 52-week high of $15.79, set on Sep 17, 2026 and 222.1% above the 52-week low of $3.65, in the middle of the past year's range. DRTS is up 137.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 207.7%.

Alpha Tau Medical has posted a net loss over the last twelve months (EPS of -$1.04), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alpha Tau Medical

Company profile

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company has a strategic collaboration agreement to develop and commercialize Alpha DaRT for the treatment of prostate cancer.

Industry
Medical/Dental Instruments
CEO
Mr. Uzi Sofer
Headquarters
Jerusalem
Employees
121

Financial highlights

Full financials

Alpha Tau Medical reported a net loss of $42.6 million, compared with a loss of $31.8 million a year earlier. Diluted earnings per share came in at -$0.53.

Alpha Tau Medical annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-42.63M$-31.75M$-29.16M$-33.76M$-27.27M
EPS (diluted)$-0.53$-0.45$-0.42$-0.53$-0.67

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$20.60+75.24%

  • Strong buy 2
  • Buy 3
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $16.00High $30.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 19, 2026
EPS actual vs est.
$-0.14 vs $-0.15
Surprise
+6.67%

DRTS news

All DRTS news

Alpha Tau Medical peers

Health Care sector
DRTS peer companies
CompanyPrice% ChgMarket capCompare
SIBNSI-BONE Inc.23.73-0.08%$1.07Bvs DRTS
IRMDiRadimed Corporation81.02-0.30%$1.04Bvs DRTS
IARTIntegra LifeSciences Holdings Corporation13.25-2.21%$1.03Bvs DRTS
ATECAlphatec Holdings Inc.6.68-3.19%$1.02Bvs DRTS
SGPSpyGlass Pharma Inc.30.43-1.14%$1.02Bvs DRTS
TNDMTandem Diabetes Care Inc.17.46+3.93%$1.22Bvs DRTS
NVCRNovoCure Limited10.71+0.19%$1.25Bvs DRTS
AORTArtivion Inc.18.16-2.00%$886.02Mvs DRTS

Indexes, lists and sector

Alpha Tau Medical stock FAQ

What is Alpha Tau Medical's stock price today?

DRTS last traded at $11.76 as of Nov 20, 4:00 PM EST, up 3.93% on the day. Prices are delayed at least 15 minutes.

Who is Alpha Tau Medical's CEO?

Mr. Uzi Sofer is the chief executive officer of Alpha Tau Medical Ltd., which has about 121 employees.

What is the DRTS 52-week high?

The 52-week high for DRTS is $15.79 and the 52-week low is $3.65. The stock is currently 25.6% below its high.

Compare DRTS